Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Buy
62
SMSZF Quote, Financials, Valuation and Earnings
Last price:
$10.31
Seasonality move
:
-5.99%
Day range:
$10.31 - $10.31
52-week range:
$6.91 - $12.52
Dividend yield:
1.79%
P/E ratio:
17.27x
P/S ratio:
2.06x
P/B ratio:
2.84x
Volume:
--
Avg. volume:
--
1-year change:
-17.63%
Market cap:
$846.2M
Revenue:
$399.8M
EPS (TTM):
$0.60
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SMSZF
SMS Co., Ltd.
|
-- | -- | -- | -- | -- |
|
HLOSF
Healios KK
|
-- | -- | -- | -- | -- |
|
PPTDF
PeptiDream Inc.
|
-- | -- | -- | -- | -- |
|
SOLTF
Nxera Pharma Co., Ltd.
|
-- | -- | -- | -- | -- |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$7.8B | -- | 3.82% | -- | $17.93 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SMSZF
SMS Co., Ltd.
|
$10.31 | -- | $846.2M | 17.27x | $0.18 | 1.79% | 2.06x |
|
HLOSF
Healios KK
|
$2.31 | -- | $266.6M | -- | $0.00 | 0% | 362.71x |
|
PPTDF
PeptiDream Inc.
|
$12.80 | -- | $1.7B | 13.79x | $0.00 | 0% | 13.79x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$5.34 | -- | $483.2M | -- | $0.00 | 0% | 2.50x |
|
STMM
Stemcell Holdings, Inc.
|
$0.06 | -- | $60M | -- | $0.00 | 0% | 0.17x |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$14.90 | $17.93 | $47.1B | 189.09x | $0.32 | 4.44% | 1.60x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SMSZF
SMS Co., Ltd.
|
16.54% | 1.049 | 6.97% | 0.90x |
|
HLOSF
Healios KK
|
47.23% | -1.205 | 3.71% | 1.23x |
|
PPTDF
PeptiDream Inc.
|
25.86% | 0.045 | 8.66% | 4.05x |
|
SOLTF
Nxera Pharma Co., Ltd.
|
49.02% | 1.721 | 73.82% | 2.21x |
|
STMM
Stemcell Holdings, Inc.
|
-- | 0.000 | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
39.45% | -0.563 | 68.02% | 0.64x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SMSZF
SMS Co., Ltd.
|
$81M | $5.3M | 14.21% | 16.59% | 5.24% | -- |
|
HLOSF
Healios KK
|
-$637.4K | -$5.2M | -86.08% | -194.37% | -4022.21% | -$5.3M |
|
PPTDF
PeptiDream Inc.
|
$11.3M | -$9.7M | -7.71% | -10.42% | -33.1% | -$12.5M |
|
SOLTF
Nxera Pharma Co., Ltd.
|
$27.7M | -$23.7M | -4.62% | -9.2% | -51.66% | -$20.9M |
|
STMM
Stemcell Holdings, Inc.
|
-- | -- | -- | -- | -- | -- |
|
TAK
Takeda Pharmaceutical Co., Ltd.
|
$3.6B | $763.2M | 0.33% | 0.55% | 10.11% | $2B |
SMS Co., Ltd. vs. Competitors
-
Which has Higher Returns SMSZF or HLOSF?
Healios KK has a net margin of 7.11% compared to SMS Co., Ltd.'s net margin of -9751.87%. SMS Co., Ltd.'s return on equity of 16.59% beat Healios KK's return on equity of -194.37%.
Company Gross Margin Earnings Per Share Invested Capital SMSZFSMS Co., Ltd.80.72% $0.09 $356.8M HLOSFHealios KK-494.88% $0.03 $37.8M -
What do Analysts Say About SMSZF or HLOSF?
SMS Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Healios KK has an analysts' consensus of -- which suggests that it could fall by --. Given that SMS Co., Ltd. has higher upside potential than Healios KK, analysts believe SMS Co., Ltd. is more attractive than Healios KK.
Company Buy Ratings Hold Ratings Sell Ratings SMSZFSMS Co., Ltd.0 0 0 HLOSFHealios KK0 0 0 -
Is SMSZF or HLOSF More Risky?
SMS Co., Ltd. has a beta of 0.083, which suggesting that the stock is 91.714% less volatile than S&P 500. In comparison Healios KK has a beta of 0.210, suggesting its less volatile than the S&P 500 by 78.954%.
-
Which is a Better Dividend Stock SMSZF or HLOSF?
SMS Co., Ltd. has a quarterly dividend of $0.18 per share corresponding to a yield of 1.79%. Healios KK offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SMS Co., Ltd. pays 40.17% of its earnings as a dividend. Healios KK pays out -- of its earnings as a dividend. SMS Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMSZF or HLOSF?
SMS Co., Ltd. quarterly revenues are $100.4M, which are larger than Healios KK quarterly revenues of $128.8K. SMS Co., Ltd.'s net income of $7.1M is higher than Healios KK's net income of $3.8M. Notably, SMS Co., Ltd.'s price-to-earnings ratio is 17.27x while Healios KK's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SMS Co., Ltd. is 2.06x versus 362.71x for Healios KK. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMSZFSMS Co., Ltd.2.06x 17.27x $100.4M $7.1M HLOSFHealios KK362.71x -- $128.8K $3.8M
-
Which has Higher Returns SMSZF or PPTDF?
PeptiDream Inc. has a net margin of 7.11% compared to SMS Co., Ltd.'s net margin of -25.38%. SMS Co., Ltd.'s return on equity of 16.59% beat PeptiDream Inc.'s return on equity of -10.42%.
Company Gross Margin Earnings Per Share Invested Capital SMSZFSMS Co., Ltd.80.72% $0.09 $356.8M PPTDFPeptiDream Inc.38.71% -$0.06 $480.4M -
What do Analysts Say About SMSZF or PPTDF?
SMS Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand PeptiDream Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that SMS Co., Ltd. has higher upside potential than PeptiDream Inc., analysts believe SMS Co., Ltd. is more attractive than PeptiDream Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMSZFSMS Co., Ltd.0 0 0 PPTDFPeptiDream Inc.0 0 0 -
Is SMSZF or PPTDF More Risky?
SMS Co., Ltd. has a beta of 0.083, which suggesting that the stock is 91.714% less volatile than S&P 500. In comparison PeptiDream Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.146%.
-
Which is a Better Dividend Stock SMSZF or PPTDF?
SMS Co., Ltd. has a quarterly dividend of $0.18 per share corresponding to a yield of 1.79%. PeptiDream Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SMS Co., Ltd. pays 40.17% of its earnings as a dividend. PeptiDream Inc. pays out -- of its earnings as a dividend. SMS Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMSZF or PPTDF?
SMS Co., Ltd. quarterly revenues are $100.4M, which are larger than PeptiDream Inc. quarterly revenues of $29.3M. SMS Co., Ltd.'s net income of $7.1M is higher than PeptiDream Inc.'s net income of -$7.4M. Notably, SMS Co., Ltd.'s price-to-earnings ratio is 17.27x while PeptiDream Inc.'s PE ratio is 13.79x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SMS Co., Ltd. is 2.06x versus 13.79x for PeptiDream Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMSZFSMS Co., Ltd.2.06x 17.27x $100.4M $7.1M PPTDFPeptiDream Inc.13.79x 13.79x $29.3M -$7.4M
-
Which has Higher Returns SMSZF or SOLTF?
Nxera Pharma Co., Ltd. has a net margin of 7.11% compared to SMS Co., Ltd.'s net margin of -24.76%. SMS Co., Ltd.'s return on equity of 16.59% beat Nxera Pharma Co., Ltd.'s return on equity of -9.2%.
Company Gross Margin Earnings Per Share Invested Capital SMSZFSMS Co., Ltd.80.72% $0.09 $356.8M SOLTFNxera Pharma Co., Ltd.60.42% -$0.13 $872.1M -
What do Analysts Say About SMSZF or SOLTF?
SMS Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Nxera Pharma Co., Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that SMS Co., Ltd. has higher upside potential than Nxera Pharma Co., Ltd., analysts believe SMS Co., Ltd. is more attractive than Nxera Pharma Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SMSZFSMS Co., Ltd.0 0 0 SOLTFNxera Pharma Co., Ltd.0 0 0 -
Is SMSZF or SOLTF More Risky?
SMS Co., Ltd. has a beta of 0.083, which suggesting that the stock is 91.714% less volatile than S&P 500. In comparison Nxera Pharma Co., Ltd. has a beta of 0.029, suggesting its less volatile than the S&P 500 by 97.149%.
-
Which is a Better Dividend Stock SMSZF or SOLTF?
SMS Co., Ltd. has a quarterly dividend of $0.18 per share corresponding to a yield of 1.79%. Nxera Pharma Co., Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SMS Co., Ltd. pays 40.17% of its earnings as a dividend. Nxera Pharma Co., Ltd. pays out -- of its earnings as a dividend. SMS Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMSZF or SOLTF?
SMS Co., Ltd. quarterly revenues are $100.4M, which are larger than Nxera Pharma Co., Ltd. quarterly revenues of $45.8M. SMS Co., Ltd.'s net income of $7.1M is higher than Nxera Pharma Co., Ltd.'s net income of -$11.3M. Notably, SMS Co., Ltd.'s price-to-earnings ratio is 17.27x while Nxera Pharma Co., Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SMS Co., Ltd. is 2.06x versus 2.50x for Nxera Pharma Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMSZFSMS Co., Ltd.2.06x 17.27x $100.4M $7.1M SOLTFNxera Pharma Co., Ltd.2.50x -- $45.8M -$11.3M
-
Which has Higher Returns SMSZF or STMM?
Stemcell Holdings, Inc. has a net margin of 7.11% compared to SMS Co., Ltd.'s net margin of --. SMS Co., Ltd.'s return on equity of 16.59% beat Stemcell Holdings, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SMSZFSMS Co., Ltd.80.72% $0.09 $356.8M STMMStemcell Holdings, Inc.-- -- -- -
What do Analysts Say About SMSZF or STMM?
SMS Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Stemcell Holdings, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that SMS Co., Ltd. has higher upside potential than Stemcell Holdings, Inc., analysts believe SMS Co., Ltd. is more attractive than Stemcell Holdings, Inc..
Company Buy Ratings Hold Ratings Sell Ratings SMSZFSMS Co., Ltd.0 0 0 STMMStemcell Holdings, Inc.0 0 0 -
Is SMSZF or STMM More Risky?
SMS Co., Ltd. has a beta of 0.083, which suggesting that the stock is 91.714% less volatile than S&P 500. In comparison Stemcell Holdings, Inc. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock SMSZF or STMM?
SMS Co., Ltd. has a quarterly dividend of $0.18 per share corresponding to a yield of 1.79%. Stemcell Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SMS Co., Ltd. pays 40.17% of its earnings as a dividend. Stemcell Holdings, Inc. pays out -- of its earnings as a dividend. SMS Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SMSZF or STMM?
SMS Co., Ltd. quarterly revenues are $100.4M, which are larger than Stemcell Holdings, Inc. quarterly revenues of --. SMS Co., Ltd.'s net income of $7.1M is higher than Stemcell Holdings, Inc.'s net income of --. Notably, SMS Co., Ltd.'s price-to-earnings ratio is 17.27x while Stemcell Holdings, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SMS Co., Ltd. is 2.06x versus 0.17x for Stemcell Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMSZFSMS Co., Ltd.2.06x 17.27x $100.4M $7.1M STMMStemcell Holdings, Inc.0.17x -- -- --
-
Which has Higher Returns SMSZF or TAK?
Takeda Pharmaceutical Co., Ltd. has a net margin of 7.11% compared to SMS Co., Ltd.'s net margin of -1.05%. SMS Co., Ltd.'s return on equity of 16.59% beat Takeda Pharmaceutical Co., Ltd.'s return on equity of 0.55%.
Company Gross Margin Earnings Per Share Invested Capital SMSZFSMS Co., Ltd.80.72% $0.09 $356.8M TAKTakeda Pharmaceutical Co., Ltd.47.41% -$0.03 $79.7B -
What do Analysts Say About SMSZF or TAK?
SMS Co., Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Takeda Pharmaceutical Co., Ltd. has an analysts' consensus of $17.93 which suggests that it could grow by 20.32%. Given that Takeda Pharmaceutical Co., Ltd. has higher upside potential than SMS Co., Ltd., analysts believe Takeda Pharmaceutical Co., Ltd. is more attractive than SMS Co., Ltd..
Company Buy Ratings Hold Ratings Sell Ratings SMSZFSMS Co., Ltd.0 0 0 TAKTakeda Pharmaceutical Co., Ltd.3 0 0 -
Is SMSZF or TAK More Risky?
SMS Co., Ltd. has a beta of 0.083, which suggesting that the stock is 91.714% less volatile than S&P 500. In comparison Takeda Pharmaceutical Co., Ltd. has a beta of 0.032, suggesting its less volatile than the S&P 500 by 96.811%.
-
Which is a Better Dividend Stock SMSZF or TAK?
SMS Co., Ltd. has a quarterly dividend of $0.18 per share corresponding to a yield of 1.79%. Takeda Pharmaceutical Co., Ltd. offers a yield of 4.44% to investors and pays a quarterly dividend of $0.32 per share. SMS Co., Ltd. pays 40.17% of its earnings as a dividend. Takeda Pharmaceutical Co., Ltd. pays out 242.25% of its earnings as a dividend. SMS Co., Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future, but Takeda Pharmaceutical Co., Ltd.'s is not.
-
Which has Better Financial Ratios SMSZF or TAK?
SMS Co., Ltd. quarterly revenues are $100.4M, which are smaller than Takeda Pharmaceutical Co., Ltd. quarterly revenues of $7.5B. SMS Co., Ltd.'s net income of $7.1M is higher than Takeda Pharmaceutical Co., Ltd.'s net income of -$79.5M. Notably, SMS Co., Ltd.'s price-to-earnings ratio is 17.27x while Takeda Pharmaceutical Co., Ltd.'s PE ratio is 189.09x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SMS Co., Ltd. is 2.06x versus 1.60x for Takeda Pharmaceutical Co., Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SMSZFSMS Co., Ltd.2.06x 17.27x $100.4M $7.1M TAKTakeda Pharmaceutical Co., Ltd.1.60x 189.09x $7.5B -$79.5M
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
54
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
57
Is GOOG Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 38x
Alerts
Sell
1
LW alert for Dec 22
Lamb Weston Holdings, Inc. [LW] is down 2.59% over the past day.
Buy
54
BMRN alert for Dec 22
BioMarin Pharmaceutical, Inc. [BMRN] is down 3.03% over the past day.
Buy
82
RKLB alert for Dec 22
Rocket Lab Corp. [RKLB] is up 9.97% over the past day.
